Biotech CEOs Must Understand: Typical Legal Risks and Mitigation Strategies in Pharmaceutical Licensing Transactions
Business development (BD) activities are becoming increasingly active. From the perspective of biotech companies, the process involves: pre-collaboration—organizing the product pipeline and positioning, identifying potential partners, and maintaining proactive external engagement; milestones—finalizing collaborations and successfully signing agreements; post-collaboration—ensuring steady progress of the partnership and maintaining effective communication and strong collaborative relationships. However, signing an agreement is not merely a milestone worth celebrating; more importantly, the agreement itself contains risk factors that can impact the advancement of the collaboration. These risks require deep understanding and high-level attention from CEOs, rather than being left solely to those responsible for agreement execution.
Hereby, VCBeat New Medicine atSeptember 7 (Thursday) 20:00 (Online), invited Mr. Gu Long, a partner at AnJie Broad Law Firm with extensive practical experience, to deliver a presentation on “Typical Risks and Response Strategies in Pharmaceutical Licensing Transactions”, we will provide a thematic sharing from the dimensions of licensing transaction types and characteristics, risk mitigation, and implementation recommendations. Stay tuned.
*Live Streaming Platform [VB100 Mini Program], Scan the Poster QR Code to Register and Reserve
*Add the assistant, connect with attendees, and join the discussion group
Guest Introduction
Gu Long
Partner, AnJie & Broad Law Firm
Mr. Gu Long is a Partner at AnJie Broader Law Firm, based in its Shanghai office. His primary practice areas include cross-border investment and mergers & acquisitions, private equity and venture capital, as well as various types of business development (BD) transactions and compliance and regulatory advisory services in the healthcare and pharmaceutical sectors.
In the field of mergers and acquisitions, Mr. Gu has represented numerous multinational corporations, large state-owned enterprises, and private enterprises in global and cross-border equity and asset acquisition transactions. In the realm of private equity and venture capital, he has acted for both industry-leading strategic investors and various RMB and USD funds, completing a substantial number of equity investment transactions with onshore and offshore structures.
Mr. Gu possesses extensive experience in the healthcare and pharmaceutical sectors, with the capability to deeply engage in projects such as investment and M&A, cross-border commercial licensing, collaborative R&D, transformation of scientific and technological achievements, and distribution and promotional partnerships. The subject matters of these collaborations encompass not only traditional biopharmaceuticals, improved new drugs, high-end medical devices, and healthcare services, but also emerging fields such as cell and gene therapy, nucleic acid drugs and delivery vectors, antibody-drug conjugates (ADCs), digital therapeutics, AI-driven drug discovery, innovative material platforms, and novel vaccine technologies. Mr. Gu frequently provides compliance training, business model review and validation, as well as regulatory and legal advisory services to clients in this sector. His client base includes foreign pharmaceutical companies, state-owned and private pharmaceutical industry groups, innovative drug incubation platforms and R&D enterprises, internet healthcare companies, and private equity funds investing in this field.
Company Profile
AboutAnJie Broad Law Firm
AnJie & Broad Law Firm is a full-service, multi-practice area comprehensive law firm. The firm adopts an integrated management model, adheres to unified legal service standards, and implements a standardized client service system, committed to providing clients with high-quality, efficient, and tailored legal services.
AnJie & Broad Law Firm has experienced rapid growth, demonstrating innovation and a deep understanding of client needs while delivering first-class legal services. The firm boasts extensive experience and an outstanding track record in the following practice areas: mergers and acquisitions; antitrust and anti-unfair competition; private equity and venture capital; capital markets and securities; real estate; healthcare and life sciences; intellectual property; dispute resolution; labor and employment; outbound investment; insurance and reinsurance; banking and finance; energy and natural resources; international trade; foreign direct investment; information, communications, technology, and media; private wealth management; and culture, arts, entertainment, and sports.
AnJie Broad was founded by a group of senior lawyers from diverse practice areas. The firm’s key partners graduated from the most prestigious law schools in China and abroad, and have gained extensive experience working at top-tier international law firms.
AnJie & Broad Law Firm and many of its partners have been highly recommended by various authoritative legal media, including Chambers & Partners, Who’s Who Legal, The Legal 500, IFLR1000, Asialaw Profiles, Asia Legal Business, LEGALBAND, Benchmark Litigation, and China Business Law Journal.
Organizer Introduction
About VCBeat New Medicine
VBMed is a media and research platform under VCBeat that focuses on the biopharmaceutical sector. It delivers “in-depth” and “incremental” communication value to innovators and entrepreneurs through two dimensions: content and operations. In terms of content, it features exclusive financing announcements, corporate interviews, the “Drug Developers” column, in-depth industry analyses, and sector reports. On the operational front, its flagship program “VB Think Tank” focuses on practical challenges, discusses industry trends, and fosters tangible collaborations through the exchange of ideas.
Thematic Achievements:[IPO Financial Report Analysis]【iPSC】[Nuclear Medicine][Protein Degraders][Upstream Tools][Synthetic Biology][Organoids][VB Think Tank]etc.
About VBInsight Salon
VB Think Tank is one of VCBeat’s flagship events, serving as a face-to-face platform centered on exploring solutions in the pharmaceutical and healthcare sectors, with the mission to “focus on practical challenges and discuss industry trends.” The event conducts in-depth discussions, analyses, and exchanges on the current development status of core themes, addressing encountered difficulties, pain points, and barriers. Meanwhile, it gains a thorough understanding of the resource endowments of participating enterprises, fostering practical collaborations through intellectual exchange. “Each session features one theme, one medium, and one ecosystem.”
■ Previous Related Activities
▲ Live Streaming Room
▲ Live Replay
▲panel
▲ Highlights